WHO ICTRP trial
A randomized double-blind controlled trial to assess the benefits of olanzapine…
DRKS00003603 · German Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | DRKS00003603 |
|---|---|
| Public title | A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients.-COMBINE |
| Scientific title | A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients.-COMBINE - Combine-study |
| Primary sponsor | Universitätsklinikum Düsseldorf |
| Registry | German Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 4 |
| Countries | Germany |
| Conditions | F20 F25;Schizophrenia;Schizoaffective disorders |
| Interventions | Group 1: amisulpride 400-800 mg/d + olanzapine 10-20 mg/d for 16 weeks Group 2: amisulpride 400-800 mg/d + Placebo for 16 weeks Group 3: olanzapine 10-20 mg/d + Placebo for 16 weeks |
| Registration date | May 18, 2012 |
| Target size | 399 |
| Secondary IDs | 2011-002463-20;4038052 |
| Registry page | drks.de |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: